We are live on ! Find out more
SLG

Stanley-Laman Group Portfolio holdings

AUM $814M
1-Year Est. Return 40.24%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+40.24%
3 Year Est. Return
+82.87%
5 Year Est. Return
+77.64%
10 Year Est. Return
+275.61%
AUM
$407M
AUM Growth
-$38.3M
Cap. Flow
-$52.4M
Cap. Flow %
-12.88%
Top 10 Hldgs %
19.3%
Holding
282
New
19
Increased
67
Reduced
110
Closed
63

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$6.14M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$5.93M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.36M
4
ALBO
Albireo Pharma Inc
ALBO
+$1.07M
5
ZYME icon
Zymeworks
ZYME
+$808K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.83M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.78M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.57M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.53M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$966K

Sector Composition

Rank Sector Weight
1 Industrials 19.96%
2 Technology 18%
3 Healthcare 15.75%
4 Materials 7.84%
5 Financials 7.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BALL icon
26
Ball Corp
BALL
$16.7B
$4.48M 1.1%
101,846
-8,851
-8% -$360K
FUL icon
27
H.B. Fuller
FUL
$3.06B
$4.38M 1.08%
84,695
-6,447
-7% -$364K
IOVA icon
28
Iovance Biotherapeutics
IOVA
$2.23B
$4.24M 1.04%
+377,260
New +$5.36M
LECO icon
29
Lincoln Electric
LECO
$13.8B
$4.19M 1.03%
44,832
-3,428
-7% -$317K
PFE icon
30
Pfizer
PFE
$143B
$3.96M 0.97%
94,723
-1,192
-1% -$45.9K
MDU icon
31
MDU Resources
MDU
$4.42B
$3.91M 0.96%
399,890
-32,460
-8% -$347K
CSCO icon
32
Cisco
CSCO
$441B
$3.73M 0.92%
76,563
-238
-0.3% -$10.7K
INGR icon
33
Ingredion
INGR
$6.47B
$3.71M 0.91%
35,324
-2,766
-7% -$282K
BERY
34
DELISTED
Berry Global Group, Inc.
BERY
$3.35M 0.82%
75,303
-7,737
-9% -$340K
HON icon
35
Honeywell
HON
$71.3B
$3.1M 0.76%
20,612
-482
-2% -$68.3K
FBIN icon
36
Fortune Brands Innovations
FBIN
$6.14B
$3.09M 0.76%
69,132
-6,169
-8% -$290K
PX
37
DELISTED
Praxair Inc
PX
$2.95M 0.72%
18,351
-618
-3% -$99.3K
RTX icon
38
RTX Corp
RTX
$261B
$2.94M 0.72%
33,431
-734
-2% -$61.6K
CYBR
39
DELISTED
CyberArk
CYBR
$2.83M 0.69%
35,382
+511
+1% +$35.9K
IBM icon
40
IBM
IBM
$200B
$2.77M 0.68%
19,129
-683
-3% -$95.4K
AKBA icon
41
Akebia Therapeutics
AKBA
$359M
$2.66M 0.65%
301,182
-40,307
-12% -$361K
BA icon
42
Boeing
BA
$169B
$2.47M 0.61%
6,649
-53
-0.8% -$18.6K
EXC icon
43
Exelon
EXC
$47.3B
$2.46M 0.61%
79,104
-1,587
-2% -$48.8K
PAYX icon
44
Paychex
PAYX
$40.7B
$2.44M 0.6%
33,192
-688
-2% -$49.4K
CNA icon
45
CNA Financial
CNA
$14.1B
$2.41M 0.59%
52,773
-812
-2% -$37.5K
WMT icon
46
Walmart Inc
WMT
$909B
$2.41M 0.59%
76,869
-2,148
-3% -$65.7K
TFC icon
47
Truist Financial
TFC
$65.4B
$2.33M 0.57%
47,992
-922
-2% -$47.3K
GILD icon
48
Gilead Sciences
GILD
$167B
$2.27M 0.56%
29,433
-297
-1% -$22.4K
CME icon
49
CME Group
CME
$88.5B
$2.25M 0.55%
13,215
-219
-2% -$36.9K
VZ icon
50
Verizon
VZ
$182B
$2.22M 0.55%
41,630
-6,726
-14% -$356K
1
2
3 4 5

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $812M AUM 17.34% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Stanley-Laman Group's Q3 2018 Portfolio in Review

As of Q3 2018, Stanley-Laman Group held 282 positions worth $407M, down 8.6% from $445M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Stanley-Laman Group withdrew a net $52.4M in Q3 2018, closing 63 positions and reducing 110 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $8.83M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 18% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Stanley-Laman Group opened a new position in Acceleron Pharma worth $7.16M.

  • Stanley-Laman Group's largest Q3 2018 buy was Acceleron Pharma: 125,020 shares worth $7.16M.
  • Stanley-Laman Group added most to Prudential Financial in Q3 2018, an estimated $152K increase.
  • Stanley-Laman Group's biggest Q3 2018 reduction was Hortonworks, Inc., cutting an estimated $629K.
  • Stanley-Laman Group fully exited Neurocrine Biosciences in Q3 2018, selling an estimated $8.83M.
  • Stanley-Laman Group's ten largest holdings make up 19% of its $407M portfolio in Q3 2018.
  • Stanley-Laman Group opened 19 new positions and closed 63 in Q3 2018.
  • Stanley-Laman Group's portfolio value fell 8.6% quarter-over-quarter to $407M.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.